ID

33722

Descripción

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT01326026

Link

https://clinicaltrials.gov/show/NCT01326026

Palabras clave

Versiones (1)
  1. 20/12/18 20/12/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

20 de diciembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Diabetes NCT01326026

Inglés

Eligibility Diabetes NCT01326026

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01326026
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (visit 2)
Descripción

Diabetes Mellitus, Non-Insulin-Dependent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0011860
current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other oads including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase iv (dpp-iv) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (tzds) all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily
Descripción

Metformin | Combined Modality Therapy | Antidiabetics Oral Quantity | Pills Insulin Release | Sulfonylurea | Glinide | DPP-4 Inhibitor | alpha-Glucosidase Inhibitors | Thiazolidinediones | Pharmaceutical Preparations Dose unchanged

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0025598
UMLS CUI [2]
C0009429
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C0994475
UMLS CUI [4,2]
C0021641
UMLS CUI [4,3]
C1283071
UMLS CUI [5]
C0038766
UMLS CUI [6]
C2266929
UMLS CUI [7]
C3537225
UMLS CUI [8]
C1299007
UMLS CUI [9]
C1257987
UMLS CUI [10,1]
C0013227
UMLS CUI [10,2]
C0178602
UMLS CUI [10,3]
C0442739
hba1c 7.0-10.0% (both inclusive) by central laboratory analysis
Descripción

Hemoglobin A1c measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0474680
bmi (body mass index) no higher than 45.0 kg/m^2
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with glucagon-like peptide 1 (glp-1) receptor agonist within the last 12 weeks prior to visit 2
Descripción

GLP-1 Receptor Agonist

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2917359
suffer from a life threatening disease (e.g. cancer)
Descripción

Life threatening illness | Malignant Neoplasms

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3846017
UMLS CUI [2]
C0006826
females of childbearing potential who are pregnant (as determined by central laboratory beta-human chorionic gonadotropin (beta-hcg), breast feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive methods as required by law or practise [for germany, adequate contraceptive methods are: implants, injectables, combined oral contraceptives, hormonal iud, sexual abstinence or vasectomised partner])
Descripción

Pregnancy Serum pregnancy test (B-HCG) | Breast Feeding | Pregnancy, Planned | Childbearing Potential Contraceptive methods Absent | Contraceptive implant | Injectable contraception | Combined Oral Contraceptives | Intrauterine Devices, Medicated | Sexual Abstinence | Partner had vasectomy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0430060
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
UMLS CUI [4,1]
C3831118
UMLS CUI [4,2]
C0700589
UMLS CUI [4,3]
C0332197
UMLS CUI [5]
C1657106
UMLS CUI [6]
C1262153
UMLS CUI [7]
C0009906
UMLS CUI [8]
C0021902
UMLS CUI [9]
C0036899
UMLS CUI [10]
C0420842
Volver a la parte superior de la página

Similar models

Eligibility Diabetes NCT01326026

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01326026
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (visit 2)
boolean
C0011860 (UMLS CUI [1])
Metformin | Combined Modality Therapy | Antidiabetics Oral Quantity | Pills Insulin Release | Sulfonylurea | Glinide | DPP-4 Inhibitor | alpha-Glucosidase Inhibitors | Thiazolidinediones | Pharmaceutical Preparations Dose unchanged
Item
current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other oads including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase iv (dpp-iv) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (tzds) all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily
boolean
C0025598 (UMLS CUI [1])
C0009429 (UMLS CUI [2])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0994475 (UMLS CUI [4,1])
C0021641 (UMLS CUI [4,2])
C1283071 (UMLS CUI [4,3])
C0038766 (UMLS CUI [5])
C2266929 (UMLS CUI [6])
C3537225 (UMLS CUI [7])
C1299007 (UMLS CUI [8])
C1257987 (UMLS CUI [9])
C0013227 (UMLS CUI [10,1])
C0178602 (UMLS CUI [10,2])
C0442739 (UMLS CUI [10,3])
Hemoglobin A1c measurement
Item
hba1c 7.0-10.0% (both inclusive) by central laboratory analysis
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
bmi (body mass index) no higher than 45.0 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
GLP-1 Receptor Agonist
Item
treatment with glucagon-like peptide 1 (glp-1) receptor agonist within the last 12 weeks prior to visit 2
boolean
C2917359 (UMLS CUI [1])
Life threatening illness | Malignant Neoplasms
Item
suffer from a life threatening disease (e.g. cancer)
boolean
C3846017 (UMLS CUI [1])
C0006826 (UMLS CUI [2])
Pregnancy Serum pregnancy test (B-HCG) | Breast Feeding | Pregnancy, Planned | Childbearing Potential Contraceptive methods Absent | Contraceptive implant | Injectable contraception | Combined Oral Contraceptives | Intrauterine Devices, Medicated | Sexual Abstinence | Partner had vasectomy
Item
females of childbearing potential who are pregnant (as determined by central laboratory beta-human chorionic gonadotropin (beta-hcg), breast feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive methods as required by law or practise [for germany, adequate contraceptive methods are: implants, injectables, combined oral contraceptives, hormonal iud, sexual abstinence or vasectomised partner])
boolean
C0032961 (UMLS CUI [1,1])
C0430060 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C1657106 (UMLS CUI [5])
C1262153 (UMLS CUI [6])
C0009906 (UMLS CUI [7])
C0021902 (UMLS CUI [8])
C0036899 (UMLS CUI [9])
C0420842 (UMLS CUI [10])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial